Already have a subscription?Sign In
Log in to see the full chart
Log in or register for a free account to get full, unrestricted access to this chart
Log in to see the full chart
October 19, 2021
US Payers and Employers Who View Prescription Digital Therapeutics (PDTs) as an Effective Tool for Treating Unmet Needs in Select Diseases, Summer 2021 (% of respondents in each group)
Note
Respondents were asked, "Do you view PDTs as an effective tool for treating unmet needs in the diseases areas below? Please select all that apply."Methodology
Data is from the October 2021 Pear Therapeutics and Avalere report titled "Pear Prescription Digital Therapeutics (PDT) Digest." 40 US payers (n=30) and employers (n=10), who are familiar with PDT, were surveyed during summer 2021. 75% of the respondents was payer or pharmacy benefit managers, and 25% was employer or employer benefits consultants who represented employer self-insured groups. The payer respondents collectively represented 192 million covered lives.Featured In
The Rise of Digital TherapeuticsMost Medicare Advantage plans fall short on abuse disorder coverageEmployers’ high healthcare spending opens a big opportunity for prescription digital therapeutics US employers combat high heart health costs with digital therapiesWisconsin residents get easier access to digital therapies for addiction management FDA clears H2o Therapeutics’ app for Parkinson’s DiseaseChart Title
US Payers and Employers Who View Prescription Digital Therapeutics (PDTs) as an Effective Tool for Treating Unmet Needs in Select Diseases, Summer 2021 (% of respondents in each group)Publication Date
October 19, 2021